Successful treatment association of interleukin-1 inhibitor anakinra and Janus kinase inhibitor baricitinib in Still’s disease

Scandinavian Journal of Rheumatology 2026

View at publisher
Authors: Sofia Ferreira Azevedo, Anabela Barcelos, Carolina Mazeda
DOI: 10.1080/03009742.2026.2620327
Cited by: 0
References: 8

Abstract

Biotechnological agents such as interleukin-1 (IL-1) IL-6 antagonists have revolutionized the treatment of Still’s disease (1, 2). However, a subset of patients remains challenging to manage, parti...

Fields of Study & Subjects

Autoimmune and Inflammatory Disorders Research Rheumatoid Arthritis Research and Therapies Cytokine Signaling Pathways and Interactions

Publication details

Journal / source
Scandinavian Journal of Rheumatology
Volume
55
Issue
4
Pages
308–310
Publication date
13 February 2026
Language
EN